the experiment be lessened or eliminated? Could the number of animals used be reduced ? And is the problem worth solving anyhow ?
These are the questions that research workers need to ask themselves-and to be seen to be asking themselves. The protest groups would then be left with no convincing grounds for complaint. Twenty-one years of beating beta-lactamases
Anyone who reflects on the properties required in a successful antibiotic cannot fail to be impressed by the package represented by benzylpenicillin. As a narrow-spectrum agent of exceptional selective toxicity it could scarcely be faulted but for one thing: its susceptibility to bacterial beta-lactamases, which break open its beta-lactam ring and destroy its antibacterial activity. In the 1950s and '60s the penicillin-resistant staphylococci that became epidemic in hospitals and caused so much serious sepsis did not owe their resistance to any change in the target they offered to penicillin; that target remained susceptible to the drug. The resistance was due to the production of beta-lactamases that destroyed the penicillin before it could act. Two approaches to the control of such strains were theoretically possible. One was to make or find substances which resembled penicillin sufficiently closely to mimic its many desirable properties but differed sufficiently to be unaffected by the enzyme. The other was to make or find substances that bound strongly to the beta-lactamase and blocked its action so that penicillin could act on the still susceptible target. The first of these possibilities received a great boost from the isolation of the penicillin nucleus, 6-aminopenicillanic acid,1 which led to the preparation of penicillin derivatives in great abundance and in 1960 to methicillin,2 the first penicillin highly resistant to staphylococcal penicillinase. Later came the orally active cloxacillin and the still better absorbed flucloxacillin.
Like benzylpenicillin, these compounds had little activity against Gram-negative rods, and the search for a broader spectrum penicillin was rewarded by the discovery of ampicillin and later the much better absorbed amoxycillin. In the course of this search compounds might have emerged which combined resistance to staphylococcal penicillinase with broadspectrum activity (as in the related cephalosporins), but in the event the broader spectrum agents proved to be susceptible not only to staphylococcal beta-lactamase but to beta-lactamases produced by Gram-negative rods. These Gram-negative betalactamases resembled the staphylococcal enzyme in their effects, but the picture was made much more complex by variations in the enzymes produced by different species and even different strains of the same species. These enzymes differed in their ability to degrade penicillins and cephalosporins or even particular penicillins and cephalosporins.
As more beta-lactamases able to attack successively introduced beta-lactam antibiotics have come to be recognised the prospect of combined treatment by blocking the enzymes and allowing labile antibiotics to act has appeared at the same time more attractive and less probable. Synthetic compounds designed as beta-lactamase inhibitors have produced some interesting experimental results3 but little therapeutic encouragement. The problem has been that, while labile antibiotics will inhibit and kill beta-lactamase-producing organisms in the presence of sufficient inhibitor, the available compounds have not been very active, and the concentrations needed to achieve a therapeutic effect have not been obtainable except perhaps in some cases in the urine.4
At last, however, and in the 21st anniversary year of methicillin-a compound designed to be beta-lactamase resistant-the alternative strategy of beta-lactamase blockade has come to fruition in a natural compound which again packages the properties required of a therapeutic agent. A substance now called clavulanic acid was found during systematic screening among the fermentation products of Streptomyces clavuligerus.5 This compound has relatively little antibacterial activity in its own right but is a potent and progressive inhibitor of beta-lactamases of both chromosomal and plasmid origin, including those found in Staphylococcus aureus, Escherichia coli, Klebsiella spp, Proteus mirabilis, Haemophilus influenzae, Neisseria gonorrhoeae, and Bacteroides spp.6 In the presence of clavulanic acid the minimum inhibitory concentrations of many penicillins and cephalosporins for beta-lactamase-producing strains are lowered to therapeutically attainable levels.7-10 The possibility of therapeutic use of beta-lactamase inhibition has become a reality, and other inhibitors are under investigation." 12 In the mean time the active pursuit of beta-lactamase-stable semisynthetic compounds in the methicillin tradition which are resistant to beta-lactamases and which also possess broadspectrum activity has been rewarded by a cluster of cephalosporins of remarkable activity.'3 In assessing the therapeutic potential of compounds chemically modified to develop a particular feature, in this case beta-lactamase stability, account has to be taken of the possibility that any or all of the other properties may have changed and must be re-examined and shown to be favourable. Hence the attraction of the alternative approach, in which the well-tried properties of a familiar compound are preserved and the single defect of beta-lactamase lability repaired. In practice, of course, where that repair is achieved by the addition of a second compound, a comprehensive examination of the second compound's properties is required. In addition to broad-spectrum, high-potency inhibition, it must not interact with the active antibiotic so as to impair its action on sensitive strains or interfere with its absorption and elimination. Moreover, if the new compound is to protect the labile antibiotic wherever it is called upon to act it must follow closely where the antibiotic goes. Finally, and by no means least important, it must protect the antibiotic without adding materially to the risk of treatment. In the compound recently marketed under the name Augmentin clavulanic acid is partnered by amoxycillin and the pair evidently correspond well in their pharmacokinetic behaviour14 15; they appear to be well tolerated at the recommended dosage, and have been successfully used to treat infections due to both sensitive and beta-lactamase-producing organisms affecting the respiratory and urinary tracts and the soft tissues.14 15 A major difference from the new potent beta-lactamasestable cephalosporins is that amoxycillin-clavulanic acid is active by mouth and the cephalosporins are not. A lack of oral activity in highly potent broad-spectrum compounds has generally been viewed with some equanimity since it spares us the fear of possible ill effects from gross disturbance of the normal bowel flora. At the same time the need for agents active against more resistant organisms outside hospital has been growing, since antibiotic resistance is no longer the hallmark of hospital bacteria. Inevitably over the years some patients who acquired such strains have exported them into the community either overtly-for example, in their surgical wounds or urine-or covertly, among their faecal flora. The opportunities for the spread of such organisms in the wider community are much less than they are in hospital, but they have made appreciable advances. For example, beta-lactamaseproducing staphylococci now heavily predominate among softtissue infections in outpatients,'6 and resistance to beta-lactam antibiotics has become definitely more common among urinary pathogens.'7 It is a matter of nice judgment at what point the prevalence of resistance has become sufficiently high to justify treatment with an agent active against both the resistant minority and the sensitive majority of infecting organisms, but thae activity of amoxycillin-clavulanic acid by mouth certainly brings the treatment of infections due to betalactamase-producing organisms much more readily within the reach of general practice.
Disturbance of the gut flora does not appear to have been a problem in treated patients; whether the repair to amoxycillin's beta-lactamase lability is sufficiently secure to control the emergence and overgrowth of resistant strains if the agent comes to be widely used, only time will tell.
F An obvious example is Thomas Wakley, founder of the Lancet, whose braggadocio still gives a lot of pleasure more than 150 years later. The claims could also be urged of the lesser-known but equally influential Ernest Hart, who, editing the BMJ from 1867 to 1898, was responsible for considering no fewer than 33 Parliamentary Bills in ten years, covering topics from baby farming (disguised infanticide) to the abolition of air pollution and the compulsory examination of the eyesight of railwaymen. Since Hart's death, however, it would be difficult to think of any doctor who has ranged so widely in so public a fashion. Possibly this dearth of candidates is due to the restricted audience a medical journalist is likely to have; possibly because today change in medical organisation tends to be achieved slowly rather than rapidly, and by private rather than public negotiation; possibly, again, because such change is often likely to be thrust on to the profession by outside polemicists rather than to spring from within it.
All of this could have been said until fifteen years ago. For it was then that another radical medical journalist burst on the scene with the same panache as his predecessors. Michael O'Donnell, whose appointment as editor of World Medicine was abruptly ended two weeks ago, has put both the profession and the public in his debt. He has campaigned vigorously and successfully for the apparently impossible, such as reform ofthe GMC; he has got doctors to laugh at themselves and their practices; he has highlighted the pettiness of the jacks-inoffice and their new bureaucracy; and he has exposed awkwardness that the Establishment would sooner have forgotten about.
But Michael O'Donnell's achievement has been even greater than that: by giving a large number of doctors, paramedical workers, and laymen the opportunity to express all sorts of views in clear and crisp prose he has filled a gap between the staid scientific journals on the one hand and the medical newspapers on the other. The result has been a unique mixture of the rumbustious and the civilised, of the sublime and the awful (according to your taste), often written by those who have had to be coaxed into proving that they also could write well. Not to have read Michael O'Donnell's World Medicine was to have been incomplete as a doctor.
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